SIRIUS研究PPT课件.pptVIP

www. Clinical trial In-stent Restenosis SIRIUS: 8 Month Angiographic Follow-up Restenosis Rates In-segment Restenosis Sirolimus Stent Bare Stent 91% reduction p0.001 Sirolimus Stent Bare Stent 75% reduction p0.001 Late Lumen Loss (mm) Sirolimus Stent Proximal Margin p0.001 SIRIUS: 8 Month Angiographic Follow-up Late Lumen Loss Bare Stent In-stent p0.001 Distal Margin p0.001 Sirolimus Stent Bare Stent Sirolimus Stent Bare Stent Number of In-segment Restenosis Events Prevented per 100 Patients All patients SIRIUS: Restenosis Events Prevented Diabetes LAD Small Vessels Long Lesions MACE SIRIUS